Previous Close | 16.17 |
1-Year Change | -29.51% |
6-Months Change | -50.06% |
3-Months Change | -24.69% |
Moving Avg (50d) | 20.358 |
Moving Avg (200d) | 26.772 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 429.7K |
Beta (3-Years) | 2.08 |
Revenue Growth (ttm) | 475.22% |
Net Profit Margin (ttm) | 33.53% |
Return On Assets (ttm) | 21.7% |
EPS (ttm) | -714.86 |
PE Ratio (ttm) | -0.02 |
Dividend Yield | 0% |
Asset Description: | Arcturus Therapeutics Holdings Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-19 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
15.847 | 15.362 | 15.038 | 14.553 | 13.745 | 12.936 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |